O

Oruka Therapeutics

Clinical-stage antibody therapies for psoriasis

Manager/Senior Manager of Statistical Programming

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • A BS or MS degree in life science, computer science, statistics, mathematics, or an equivalent relevant degree, and at least 5 years in a programming or statistical role.
  • At least 2 years of experience as a lead, program, or project programmer for one or more programs, including coordinating large teams of internal and/or external programmers.
  • Demonstrated leadership, collaboration, and organizational skills, with the ability to manage and oversee multiple trials simultaneously while meeting deadlines.
  • In-depth understanding of clinical-trial methodology, regulatory requirements, and Good Clinical Practice.
  • Advanced knowledge of industry standards, including CDISC standards, and a solid understanding of the development and use of standard programs.
  • SAS programming skills in procedures and options commonly used in clinical-trial reporting, including Macro language, BASE SAS, SAS/STAT, SAS/GRAPH, validation and quality control, and generating listings, tables, and figures.
  • Ability to program defensively, check results, and consistently produce accurate outputs.
  • Knowledge of FDA, EMA, and ICH regulatory guidelines relevant to clinical trials, statistics, and data handling, along with advanced knowledge of submission requirements and standards.
  • Experience contributing to the review of statistical analysis plans and developing technical programming specifications.
  • Experience outsourcing programming activities and overseeing services provided by CROs and contractors.
  • Ability to plan and manage multiple responsibilities concurrently while maintaining quality standards and meeting deadlines under pressure.

Responsibilities

  • Lead statistical programming activities for multiple clinical trials within a program or a complete development program.
  • Be accountable for timely, high-quality development and validation of all statistical programming components on assigned programs; ensure audit readiness and accuracy and reliability of statistical analysis results.
  • Serve as lead programmer to produce and/or validate tables, listings, figures, and analysis datasets for regulatory requests, publication needs, and ad hoc analyses, and write programming specifications.
  • Oversee CRO SAS programming by reviewing activities and progress to ensure projects are delivered on time and with suitable quality.
  • Work with Data Management and Biostatistics teams to ensure the accuracy of final databases, analyses, and reports; oversee study-level programming timelines with study lead biostatisticians and cross-functional teams.
  • Collaborate with biostatisticians and clinical development colleagues to develop and review TFL shells, SDTM, and ADaM specifications.
  • Identify issues and develop global tools, such as macros or graphical user interface applications, to improve the efficiency and capacity of the statistical programming group.
  • Maintain advanced knowledge of SAS software and industry requirements, including CDISC, eCTD, and Define.xml, and attend functional meetings and training.
  • Represent statistical programming at program level, in audits and inspections, and in Health Authority meetings.
  • Provide expert technical and professional recommendations and thought leadership for statistical programming at program level.
  • Follow FDA regulations for training records, guidelines, and standard operating procedures, as well as company procedures, work instructions, and department guidelines.

Desired Qualifications

  • Experience with R programming.
  • NDA submission experience.

About the Company

Oruka Therapeutics

Clinical-stage antibody therapies for psoriasis

Oruka Therapeutics develops antibody-based therapies for chronic skin diseases, focusing on plaque psoriasis and psoriatic arthritis. Its monoclonal antibodies, discovered and engineered by Paragon Therapeutics, are designed for longer dosing intervals to improve patient convenience. ORKA-001 targets IL-23p19 with an extended half-life that could allow dosing once or twice a year, while ORKA-002 targets IL-17A/F with dosing two to three times per year; both are in early-stage trials with Phase 2 planned for 2025–2026. The company aims to deliver higher skin clearance and durable remission to the large patient pool, pursuing commercialization after advancing through clinical trials; it entered public markets via a 2024 reverse merger with ARCA biopharma and raised over $475 million to fund operations through 2027.

Company size
11-50
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Oruka Therapeutics

See more jobs